A Descriptive review on various lipids and techniques used in formulation of solid lipid nanoparticles
Keywords:
Lipid, Nan particles, Biodegradable, Sanitation, HomogenizationAbstract
Solid lipid nanopaticles (SLNs) emerged in early 1990s as a next-generation drug delivery system, an alternative to traditional colloidal carriers like liposomeÊs, polymeric nanoparticles, emulsions etc. Their size range is between 1 to 1000 nm and their biodegradable and inacceptable nature make them less toxic and thus better suited to patients. SLNs have got potential applications in pharmaceutical field, cosmetics, clinical medicine and other allied sciences. Presently, formulation scientists have been focusing on SLNs as colloidal drug carriers for incorporating hydrophilic as well as lipophilic drugs. The ability to incorporate drugs into nanocarriers offers a new prototype in drug delivery which can be used for drug targeting. They hold great promise for reaching the goal of controlled and site specific drug delivery. Furthermore, SLNs have got advantage of being introduced in the body by oral, parenteral and topical routes. So the present review attempts to enlighten various lipids used in SLNs, manufacturing techniques as well as the potential applications through various routes for a variety of disorders. Furthermore, the manuscript also focuses on the fate of these lipids (constituents of SLNs) in the body and their way out (i.e. elimination).
References
. Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Del. 2011; 8: 1407–24.
. Mehnert W, Mader K. Solid lipid nanoparticles. Production, characterization and applications. Adv Drug Deliv Rev. 2001; 47:165–96.
. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2012; Article ID 750891: 1-10.
. Garud A, Singh D, Garud N. Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications. Int Current Pharm Journal. 2012; 1(11): 384-93.
. Nikam S, Mayura C, Sharma PH. Solid Lipid Nanoparticles: A Lipid Based Drug Delivery. Inovation in Pharmaceutical and Pharmacotherapy. 2014; 2(3): 365-7
. Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Sci Revs Chem Commun. 2012; 2(1): 80-102.
. Jain S, Khare P, Gulbake A, Bansal D, Jain SK. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Delivery. 2010; 17(6): 443-51.
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 697-99.
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 473-74.
. https://pubchem.ncbi.nlm.nih.gov/compound/Decanoic_acid
. https://pubchem.ncbi.nlm.nih.gov/compound/Docosanoic_acid
. https://pubchem.ncbi.nlm.nih.gov/compound/trimyristin
. https://pubchem.ncbi.nlm.nih.gov/compound/tristearin
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 290-93.
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 286-87
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 293-94.
. http://www.gattefosse.com/en/applications/compritol-888-ato.html.
. http://www.sciencelab.com/msds.php?msdsId=9923365
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 210-14.
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 722-26
. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press and American Pharmacists Association. 2009. 178-80.
. Yadav N, Khatak S, Sara UVS, Solid Lipid Nanoparticles- A Review. Int J App Pharm. 2013; 5(2): 8-18
. Ekambaram P, Sathali AH, Priyanka K. Solid lipid nanoparticles: a review. Sci. Revs. Chem. Commun. 2012; 2(1): 80-102
. Kamble VA, Jagdale DM, KadamVJ. Solid lipid nanoparticles as drug delivery system. Int J Pharma Bio Sci. 2010; 1(3); 1-9
. Nikam S, Mayura C, Sharma PH. Solid Lipid Nanoparticles: A Lipid Based Drug Delivery. Inn Pharm and Pharmacotherapy. 2014; 2 (3): 365-76
. Nair R, Kumar KSA, Priya KV, Sevukarajan M. Recent Advances in Solid Lipid Nanoparticle Based Drug Delivery Systems. J Biomed Sci and Res. 2011; 3(2): 368-84
. Garud A, Singh D, Garud N. Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications. Int Current Pharm Journal. 2012; 1(11): 384-93.
. Nagavarma BVN, Yadav HKS, Ayaz A, Vasudha S. Different techniques for preparation of polymeric nanoparticles- a review. Asian j pharm clin res. 2012; 5 suppl 1. 16-23.
. Ramteke KH, Joshi SA, Dhole SN. Solid Lipid Nanoparticle: A Review. IOSR J Pharmacy. 2012; 2(6): 34-44
. Parhi R, Padilama S. Supercritical fluid technology: a review. Advanced pharmaceutical science and technology. 2012; 1(1): 13-36
. Schubert MA, Muller GCC. Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003; 55: 125–31.
. Killeen MJ. Spray drying and spray congealing of pharmaceuticals. In Swarbrick J. Boylan Editor. In Encyclopedia of Pharmaceutical Technology. CRC Press; 2000. p. 207-222
. Yasira M, Sarac UVS. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. Acta Pharmaceutica Sinica B. 2014; 4(6): 454-63.
. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavaila-bility. J Control Release. 2006; 114(1): 53-59.
. Gaur PK, Mishra S, Bajpai M, Mishra A. Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies. Bio Med Res Int. Volume 2014; Article ID 363404: 1-9.
. Gardouh AR, Gad S, Ghonaim HM and Ghorab MM. Design and Characterization of Glyceryl Monostearate Solid Lipid Nanoparticles Prepared by High Shear Homogenization. British J Pharm Research. 2013: 3(3): 326-46.
. Nerella A, Basava RD, Devi AM. Formulation Optimization and In vitro Characterization of Letrozole Loaded Solid Lipid Nanoparticles. Int J Pharm Sci and Drug Res. 2014; 6(3): 183-88.
. Khan S, Tiwari T, Tyagi S, Bhowmik M, Joshi A, Dubey B. Preformulation studies and preperation of dithranol loaded solid lipid nanoparticles. Int J Res Dev Pharm L Sci. 2012; 1, suppl 4: 183-88.
. Venkateswarlu V, Manjunath K. Preparation characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Cont Rel. 2004; 95(3): 627-38.
. Parmar B, Mandal S, Petkar KC, Patel LD, Sawant KK. Vlasartan loaded solid lipid nanoparticles: Development, Characterization and in vitro and ex vivo evaluation. Int j pharm sci nanotech. 2011; 4(3): 1483-90.
. Aboutaleb E, Noori M, Gandomi N, Atyabi F, Fazeli MR, Jamalifar H, et al. Rassoul dinarvand improved antimycobacterial activity of rifampin using solid lipid nanoparticles. Int Nano Letters. 2012; 33(2): 1-8.
. Akbari Z, Amanlou M, Sabet JK, Golestani A. Niasar MS. Characterization of Carbamazepine-Loaded Solid Lipid Nanoparticles Prepared by Rapid Expansion of Supercritical Solution. Tropical J Pharm Res. 2014; 13 (12): 1955-61.
. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci. 2000; 10(4): 305-9.
. Chen CQY, Jing QZ, Wang XG. Preparation and Characterization of Catalase-Loaded Solid Lipid Nanoparticles Protecting Enzyme against Proteolysis. Int J Mol Sci. 2011; 12(7): 4282-93.
. Silpa N, Chakravarthi NR, Chandramouli Y, Hemanth K, Kumar P. Moxifloxacin Loaded Solid Lipid Nanoparticles (Slns): Preparation and Characterization. Asian J. Pharm. Res. Vol. 2012; 2(2): 105-112.
. Daman Z, Gilani K, Najafabadi AR , Eftekhari HR and Barghi MA, Formulation of inhalable lipid-based salbutamol sulfate microparticles by spray drying technique, DARU J Pharm Sci. 2014; 22-50
. Damge C, Michel C, Aprahamian M, Nanocapsules as carriers for oral peptide delivery. J Control Release, 1990; 13(2-3): 233–39
. Ponchel G, Montisci MJ, Dembri A, Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm, 1997; 44(1): 25-31.
. Olbrich C, Bakowski U, Lehr CM. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 2001; 77(3): 345-55.
. Pedersen N, Hansen S, Heydenreich AV, Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm, 2006; 62(2): 155–62.
. Sznitowska M, Gajewska M, Janicki S, Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm, 2001; 52(2):159–63.
. Lee WA, Ennis RD, Longenecker JP, The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm Res, 1994; 11(5): 747-50.
. Agu RU, Ugwoke MI, Armand M, The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res, 2001; 2(4): 198–209.
. Pandey R, Khuller GK. Tuberculosis, Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis2005; 85(4): 227–34.
. Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res. 2010; 35(7): 537-52.
. Muller RH, Ruhl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm. 1996; 144(1): 115-21
. Olbrich C, Muller RH. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm. 1999; 180(1): 31- 39.
. Olbrich C, Kayser O, Muller RH. Enzymatic degradation of Dynasan 114 SLN - effect of surfactants and particle size. J Nanopart Res. 2002; 4(1-2): 121-129.
. Olbrich C, Kayser O, Muller RH. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)--effect of surfactants storage time and crystallinity. Int J Pharm. 2002; 237(1-2): 119-28.
. Dong X, Mumper RJ. The metabolism of fatty alcohols in lipidnanoparticles by alcohol dehydrogenase. Drug Dev Ind Pharm. 2006; 32(8): 973-80.
. Gokce EH, Sandri G, Egrilmez S, Bonferoni MC, Guneri T, Caramella C. Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res. 2009; 34(11): 996-1003.
. Shen J, Wang Y, Ping QN, Xiao YY, Huang X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Rel. 2009; 137(3-4): 217-23.
. Yang W, Peters JI, Williams RO. Inhaled nanoparticles – A current review. Int J Pharm. 2008; 356(1-2): 239-47.
. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int. J. Pharm. 2009; 369 (1- 2): 136-43.
. Videira MA, Botelho MF, Santos AC, Gouveia LF, De Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target. 2002; 10 (8): 607-13.
